PlexiClot speaks to the needs of neurosurgeons. John M. Abrahams, a leading neurosurgeon, noted “Results for PlexiClot? Absorbable Hemostat demonstrated its speed of action & performance without manual pressure in a range-finding porcine brain trial.?Its speed of action & ability to handle robust bleeding compared to the standard of care was impressive (video link below in comments).?PlexiClot’s transparency allowed clear visual confirmation of hemostasis, a game changer from current opaque devices.?The trial highlighted the need for a clinical grade dispenser.?Future trials need more consistent wound creation so that results can be statistically analyzed.?Even so, the trial confirmed performance in earlier porcine liver trials.?Separate tests demonstrated its patented feature of gently shrinking.?Looking forward to the next set of tests. “
Endomedix, Inc.
医疗设备制造业
Montclair，New Jersey 977 位关注者
Endomedix has developed a patented device that will restructure the $1.9B absorbable hemostat market in neurosurgery.
关于我们
Endomedix is a development stage, Medical Device venture, a C corp. The Company has developed a tunable polysaccharide platform that can produce a family of new biomaterials. The first spinoff of this platform is PlexiClot? Absorbable Hemostat to control bleeding in brain & spinal surgeries, a $1.9B market. PlexiClot introduces the first fundamental innovation in bleeding control in these procedures since the current standard of care was introduced in 1945. The innovation is based on new mechanisms of action that will likely obsolete the current methods of relying on the biochemical action of thrombin and manual pressure to produce coagulation. PlexiClot will eliminate one cause of reoperations caused by current devices as documented in dozens of clinical publications. In addition to reducing the incidence of complications, PlexiClot is poised to save hospitals hundreds of millions of dollars in unreimbursed costs due to reoperation, lengthy hospital stays and early readmission to hospitals. PlexiClot’s performance has been confirmed in 3 large animal trials, and Endomedix is currently planning to scale up production. PlexiClot’s composition of matter, method of manufacture and mechanisms of action are protected by 8 issued patents, the most important of which expire in 2038. The Endomedix team is led by Richard Russo, a medical device vet with experience in prior start-ups with exits, and he is the lead cash investor. He has a history of success with new products, clinical & regulatory, and international. R&D is led by Piyush Modak, who leverages a small internal team through a constellation of renown subject matter experts. 18 neurosurgeons & physicians are investors. PlexiClot will be the 1st device approved by FDA specifically for brain surgery. This sector is marked by a high level of M&A activity, much of which occurs prior to final FDA approval. The program has drawn interest & support from surgeons and physicians, 18 of whom are investors.
- 网站
-
https://www.endomedix.com
Endomedix, Inc.的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 2-10 人
- 总部
- Montclair，New Jersey
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Biosurgery 、Neurosurgery和Bleeding Control
地点
-
主要
获取路线
1 Normal Ave
Center for Environmental and Life Sciences, Suite # 404
US，New Jersey，Montclair，07043
Endomedix, Inc.员工
-
Mathilde Coste
CFO | SaaS | MedTech | Rapid growth | VC & PE backed | Mid-size | Board Director
-
Mina S.
Vice President, Commercial Strategy and Corporate Development | FDA Breakthrough Device Designation for Seravue? | Raised > 10M | Published Co-Author…
-
Chinnapatch Tantisuwanno
Polymer chemist
-
Navyalahari Boddu
Analytical Lab Tech/Chemical Engineer
动态
-
PlexiClot speaks to the needs of neurosurgeons. John M. Abrahams, a leading neurosurgeon, noted “Results for PlexiClot? Absorbable Hemostat demonstrated its speed of action & performance without manual pressure in a range-finding porcine brain trial.?Its speed of action & ability to handle robust bleeding compared to the standard of care was impressive (video below).?PlexiClot’s transparency allowed clear visual confirmation of hemostasis, a game changer from current opaque devices.?The trial highlighted the need for a clinical grade dispenser.?Future trials need more consistent wound creation so that results can be statistically analyzed.?Even so, the trial confirmed performance in earlier porcine liver trials.?Separate tests demonstrated its patented feature of gently shrinking.?Looking forward to the next set of tests. “ https://lnkd.in/eisGJBBR
Endomedix Porcine Brain Trial LinkedIn
https://www.youtube.com/
-
Endomedix, Inc. is proud of Central Texas Angel Network support for our technology that will set the new standard of care for surgical bleeding control. #angelinvesting #neurosurgery #medtech
In 2024, CTAN welcomed eight exceptional companies to our portfolio: Endomedix, Inc., Imperium Technologies, Inc, AGED Diagnostics, ALM Ortho, Inc., Delta Development, ICHOR Vascular Inc., Add Value Machine Inc, and Rebel Medicine. These startups are tackling some of the most pressing challenges across industries like advanced medical technology, diagnostics, manufacturing, and sustainable development. Each of these companies brings a unique perspective to the challenges they’re addressing, and we’re excited to partner with them as they continue to make an impact. If you’re an #investor looking to support game-changing startups like these, there’s never been a better time to join CTAN as we kick off a new year! Learn more about becoming part of our community: www.ctan.com #angelinvesting #startups #austintx #innovation #entrepreneurs #startupfunding
-
-
"Exits, not FDA Premarket clearance, are the ultimate goal" - Richard Russo, CEO
Excited to release our 2024 report! Advancing medical tech, expanding healthcare services, or innovating in biotech? Get the HSBC Innovation Banking Venture Healthcare Report, developed by experts. Click here to read the annual report: https://lnkd.in/g_eqnRC5 #HSBCInnovationBanking
-
-
Endomedix technology & CEO Richard Russo were recently featured in an article by University City Science Center. #innovation #medtech #neurosurgery
Brain bleed technology last saw true innovation in 1945 - the same year that WWII came to an end. Having remained largely unchanged for over eight decades,?the technology is ripe for innovation. That’s where Capital Readiness alum Richard Russo & his medical device company, Endomedix, Inc., come into play. ?? Read the full story: https://lnkd.in/eCE_Vg9r
-
-
Endomedix technology & CEO Richard Russo were recently featured in an article by University City Science Center. #innovation #medtech #neurosurgery
Brain bleed technology last saw true innovation in 1945 - the same year that WWII came to an end. Having remained largely unchanged for over eight decades,?the technology is ripe for innovation. That’s where Capital Readiness alum Richard Russo & his medical device company, Endomedix, Inc., come into play. ?? Read the full story: https://lnkd.in/eCE_Vg9r
-
-
Endomedix notches another milestone! The USPTO has granted Endomedix’s 9th patent, the 3rd of the family of Method and Composition for Achievement of Hemostasis and Stable Clot Formation patents.?“PlexiClot’s patent protected technology introduces new mechanisms of action for the control of bleeding in surgery”, notes Richard Russo, Endomedix CEO. “The robust patent estate protects the composition of matter, methods of processing, and the mechanisms of action of our PlexiClot? Absorbable Hemostat.? ? Current devices rely on a biochemical agent delivered by a matrix to a bleeding site and applied with pressure to produce hemostasis. This technique was introduced in 1945.??“The current devices have a number of liabilities and performance issues when used in neurosurgery that lead to avoidable complications and significant costs.?For example, current devices swell in use and can lead to the need for reoperation.?PlexiClot’s patented mechanism of action that eliminates this threat and does not rely on either biochemical agents or manual pressure to produce hemostasis and stable clots. #neurosurgery #hemostasis #medtech #biosurgery #innovation Golden Seeds Central Texas Angel Network University City Science Center Keiretsu Forum Midwest
-
-
The European Patent Office has granted to Endomedix its 8th patent for PlexiClot? Absorbable Hemostat!?The patent’s 15 claims protect the device’s composition of matter and novel mechanisms of action and extends the protection of Endomedix IP already established in the US. PlexiClot’s patented biomaterial produces novel mechanisms of action that will reduce the high rate of revision surgery, lengthy hospital stays and early readmissions for neurosurgery patients. Central Texas Angel Network Keiretsu Forum Midwest Keiretsu Forum Mid-Atlantic Golden Seeds #neurosurgery #innovation #medtech #bleedingcontrol
-
New Jersey CSIT steps up with a grant award to support life science innovation at a NJ venture. Endomedix, Inc. thanks CSIT for the award to support an important animal trial. PlexiClot provides the first fundamental innovation in bleeding control in neurosurgery since the current Standard of Care was introduced in 1945! Judith Sheft Mahako E. #NJCSIT #innovation #neurosurgery #startup #NewJersey #biosurgery ?
-
Breakthrough MedTech ventures need high quality angel investors like Central Texas Angel Network for investments and partnership. Endomedix, Inc. #startup #neurosurgery #angelinvesting #medtech
BREAKING NEWS! CTAN proudly announces its first investment of the year, putting over $500,000 into Endomedix, Inc., a trailblazing medical technology company redefining surgical bleeding control with their groundbreaking PlexiClot? technology. "We believe in the potential of Endomedix, Inc.'s technology to address critical unmet needs in the medical community," shares Katie Russel, Executive Director of CTAN. Richard Russo, Founder and CEO of Endomedix, Inc., expresses gratitude for CTAN's support and partnership as they advance innovative solutions for surgical hemostasis. Read the full press release here: #startups #angelinvesting #austinstartups #austininnovation #angelfunding #entrepreneurs